Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Polycythemia Vera × imetelstat × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 5 Myelodysplastic Syndromes 3 Primary Myelofibrosis 2 Oligodendroglioma 2 Neuroblastoma 2 Neoplasms, Plasma Cell 2 Myeloproliferative Disorders 2 Multiple Myeloma 2 Lymphoma 2 Leukemia, Myeloid, Acute 2 Glioblastoma 2 Astrocytoma 2 Thrombocytosis 1 Thrombocythemia, Essential 1 Sezary Syndrome 1 Rhabdomyosarcoma 1 Polycythemia Vera 1 Polycythemia 1 Osteosarcoma 1 Optic Nerve Glioma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neoplasms, Neuroepithelial 1 Mycosis Fungoides 1 Lymphoproliferative Disorders 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Extranodal NK-T-Cell 1 Lung Neoplasms 1

Interventions

fludarabine phosphate 23 ruxolitinib 21 Peripheral Blood Stem Cell Transplantation 20 Cyclophosphamide 20 Busulfan 14 Whole-Body Irradiation 12 Tacrolimus 12 Mycophenolic Acid 12 Methotrexate 10 Cyclosporine 10 Antilymphocyte Serum 9 Filgrastim 7 Decitabine 7 Aspirin 7 Melphalan 6 Etoposide 6 Cytarabine 6 givinostat hydrochloride 5 givinostat 5 fludarabine 5 Radiotherapy 5 Hydroxyurea 5 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 5 peginterferon alfa-2a 4 Stem Cell Transplantation 4 Phlebotomy 4 Methylprednisolone 4 Imatinib Mesylate 4 Biopsy 4 bomedemstat 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01243073 2016-01-26

ET/PV

Geron Corporation

Phase 2 Completed

Polycythemia Vera, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon ⚡